596095-52-2

Upstream product

• 109121-41-7 (R)-4-((1S,2R)-1-benzyloxy-2-methylbut-3-enyl)-2,2-dimethyl-[1,3]dioxolane 
• 88406-01-3 2,3-O-isopropylidene-1-C-<(1R)-1-methylprop-2-enyl>-D-erythro-glycerol 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 1707-77-3 1,2:5,6-di-O-isopropylidene-D-mannitol 

Downstream Products

• 596095-57-7 (2E,4E)-(6R,7S)-7-Benzyloxy-7-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,4,6-trimethyl-hepta-2,4-dien-1-ol 
• 596095-56-6 (2E,4E)-(6R,7S)-7-Benzyloxy-7-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,4,6-trimethyl-hepta-2,4-dienoic acid methyl ester 
• 596095-58-8 (2E,4E)-(6R,7S)-7-Benzyloxy-7-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,4,6-trimethyl-hepta-2,4-dienal 

Relevant academic research and scientific papers

A divergent approach to apoptolidin and FD-891: Asymmetric preparation of a common intermediate

Biologically active Apoptolidin and FD-891 have structural similarity in their macrocyclic cores. Asymmetric preparation of a common intermediate in the total synthesis of these two macrolides is presented. A modified Masuyama Sn-allylation was employed to control the relative stereochemistry in the synthesis of the intermediate.